Annual Clinical Contract Evaluations: Are You Ready?

By AHRMM

AHRMM Webinar Image

 

Price: Member: FREE  |  Non-Member: $99.00

CEC Hours: 1

Order Webinar

 

Description:

The process of annual clinical contract evaluations can be time consuming and overwhelming, and supply chain has a unique opportunity to support the continuum of care as we expand our CQO efforts and strive to meet requirements. In this webinar, we discuss the clinical contract evaluation process, including government requirements, expectations, and improving contract performance with the use of key performance indicators.

Attendees will hear firsthand what the Dana-Farber Cancer Institute (DFCI) learned during their last Joint Commission inspection regarding the evaluation process and the effectiveness of their contracts. In addition, DFCI will share how their annual clinical contract evaluation process has matured through the improvement of existing contract management technology and the automation of the evaluation process.

 

Learning Objectives:
  • Characterize a clinical contract.
  • Explain the annual clinical contract evaluation requirements.
  • Define key performance indicators.

 

Presenters:
  • Sarah Buck — Supply Chain Business Analyst, Dana-Farber Cancer Institute
  • Susan Wills — Director Strategic Sourcing and Contracts, Dana-Farber Cancer Institute

 

Related Resources

Issue Brief
Medical Device Excise Tax - What You Should Know
The Medical Device Excise Tax, a component of the Affordable Care Act, is approaching implementation at the beginning of 2013.
Magazine & Journal Articles
Navigating the Economic Storm: A Prescriptive Approach for Healthcare Supply Chain Professionals
In this page, AHRMM recommends these 3 proactive activities in the event of economic downturn.
Advisory
CMS Releases Final Rules for CY 2011 Hospital Outpatient/ASC Payment System, Physician Fee Schedule and Home Health Payment System
An overview of the Centers for Medicare & Medicaid Services' three final rules for calendar year 2011 the outpatient prospective payment
Advisory
Medical Device Tax Next Steps
The medical device excise tax is a feature of the Affordable Care Act. It is important to be knowledgeable about the tax and its effects.
Letter/Comment
The Official Comment of AHRMM to the United States Department of Health and Human Services Food and Drug Administration (FDA) regarding Unique Device Identification for Medical Devices Docket No. FDA-2011-N-0090
AHRMM comments to the FDA regarding an amendment to the UDI proposed rule to address the UDI implementation time frame required by the 2012 Fo
Advisory
CMS Releases Proposed Rule for Hospital Value-Based Purchasing Program
The Patient Protection and Affordable Care Act of 2010 (ACA) requires the Secretary of Health and Human Services to establish a VBP program t